Nilotinib (Tasigna®) Product Review

In this Issue:

This article reviews clinical trial data in the use of the oral kinase inhibitor nilotinib (Tasigna®) for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase.

Nilotinib is available in Australia as Pharmaceutical Benefits Scheme subsidised therapy for the treatment of patients with CML, expressing the Philadelphia chromosome or the transcript – BCR-ABL – and who have a primary diagnosis of CML.

Independent commentary has been provided by Associate Professor Paula Marlton who is Head of Leukaemia and Lymphoma and Deputy Director of Haematology at the Princess Alexandra Hospital.

Please login below to download this issue (PDF)